Axsome Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Axsome Therapeutics, Inc. on February 28, 2020, reporting events occurring on that date and a press release issued on March 5, 2020. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in New York, New York. Its common stock trades on The Nasdaq Global Market under the symbol AXSM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change reported is the promotion of Mark Jacobson from Senior Vice President, Operations to Chief Operating Officer, effective February 28, 2020. Mr. Jacobson has been with the company since April 2014. No other material changes to the company's operations or financial structure are disclosed in this document.
Guidance, Outlook, and Compensation
There is no forward-looking guidance, outlook, or discussion of risks and contingencies in this filing. Regarding compensation, Mr. Jacobson will receive a base salary of $375,000 per year, effective January 1, 2020. He remains eligible for equity awards under the Company's 2015 Omnibus Incentive Compensation Plan but did not receive any new equity awards in connection with this promotion.
Key Facts for Investor Verification
- Mark Jacobson was promoted to Chief Operating Officer effective February 28, 2020.
- Mr. Jacobson's base salary is set at $375,000 annually.
- No new equity awards were granted to Mr. Jacobson as part of this promotion.
- The company is classified as an emerging growth company.
- This filing contains no financial data or operational guidance.